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The result of our previous study has shown that the K-ras mutant (pK568MRSV) transfected human adrenocortical cells can
signiﬁcantly increase cortisol production and independently cause cell transformation. The aim of this study is to investigate the
effect of the active K-ras oncogene on the cortisol production in normal human adrenocortical cells. First we used isopropyl
thiogalactoside to induce the inducible mutant K-ras expression plasmid, pK568MRSV, in the stable transfected human
adrenocortical cells. The result showed that the increase of RasGTP levels in transfected cells was time-dependent after
isopropyl thiogalactoside induction. Additionally, results from Western blot analysis revealed signiﬁcant elevation in
phosphorylation of c-Raf-1 and Mitogen-activated protein kinase. We also detected the levels of mRNA encoding Cholesterol
side-chain cleavage enzyme (P450SCC), 17a-Hydroxylase/17,20-lyase (P450c17) and 3b-Hydroxysteroid dehydrogenase
(3bHSD) were increased in human adrenocortical cells transfected with mutant K-ras after IPTG treatment. The increase of
mRNA amount in P450scc P450c17 and 3bHSD and the elevation of cortisol level were inhibited with a pretreatment of
PD098059, a speciﬁc extracellular signal-regulated kinase inhibitor. In our previous report, we proved that lovastatin, a
pharmacological inhibitor of p21
ras function, also reversed the increase of cortisol level in mutant K-ras stably transfected
human adrenocortical cells. Taken together, these ﬁndings proved that the active mutant Ras enhanced not only cell
proliferation but also steroidogenesis in steroidogenic phenotype cells by activating Raf-MEK-MAPK related signal transduction
pathway. Therefore, we believe that K-ras mutants inﬂuence regulation of steroidogenesis in adrenocortical cells through RAF-
MEK-MAPK pathway.
British Journal of Cancer (2002) 87, 1000–1005. doi:10.1038/sj.bjc.6600589 www.bjcancer.com
ã 2002 Cancer Research UK
Keywords: K-ras mutants; functional adrenal tumour; normal adrenocortical cells; cortisol secretion; RAF; MEK
Our laboratory has been studying human functional adrenocortical
tumours since 1993 (Lin et al, 1994, 1996, 1998a,b, 2000; Shu et al,
2001; Wu et al, 2002). We have found that the K-ras gene
enhanced the efﬁciency of cell proliferation and elevation of corti-
sol production in bovine adrenocortical cells. However, it did not
independently induce cell transformation (Shu et al, 2001). To
increase the credibility of our experiments, we cultured normal
human adrenocortical cells from donors for mutant K-ras gene
analysis. The cultured normal human adrenocortical cells synthe-
sised and secreted steroid hormones. The levels of cortisol and
aldosterone indicated that the cultured cells were mainly fasciculata
reticularis cells with very few contaminating glomerulosa cells (Wu
et al, 2002). The results also showed that cortisol levels of the K-ras
mutant (pK568MRSV ) transfected human adrenocortical cells were
18 to 25 times higher than that in controls. In addition, the mutant
K-ras gene could induce morphologic alterations in the transfected
adrenocortical cells (Wu et al, 2002). These studies proved that the
mutant K-ras gene takes part in steroidogenesis of human func-
tional adrenocortical cells. Nevertheless, it is not quiet clear
whether the mutant K-ras gene enhances steroidogenesis through
Mitogen-activated protein kinase (MAP kinase, MAPK) pathway
or others.
The core components of the MAPK signalling cascades are three
sequential kinases, including MAP kinase (MAPK, or extracellular
signal-regulated kinase, ERK), MAPK kinase (MAPKK, or
MAPK/ERK kinase, MEK), and MAPKK kinase (MAPKKK, or
MEK kinase, MEKK). There are three characterised MAPK signal-
ling pathways: (1) the Ras-to-MAPK signal transduction pathway
(or ERK pathway), which is responsive to signals from receptor
tyrosine kinase and some heterotrimeric G-protein-coupled recep-
tors, which promote cell proliferation or differentiation. Ras acts as
a molecular switch by cycling between active GTP-bound and inac-
tive GDP-bound states. The active RasGTP form transfers the
signal to Raf. The active Raf will phosphorylate MEK and then
the phosphorylated MEK will phosphorylate ERK1/2(MAPK).
Consequently, the phosphorylated ERK1/2 will activate a series of
target proteins such as the ribosomal protein S6 kinases (RSKs),
E1k-1, SOS, STATS, and C-Myc, which lead to consequent reac-
tions (Treisman, 1996; Fanger et al, 1997; Elion, 1998); (2) the
stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/
JNK) pathway; and (3) the p38 pathway (Robinson and Cobb,
1997; Garrington and Johnson, 1999). Many inhibitors are used
to stop signal transduction in Ras/MAPK pathway research. One
of them, PD098059, a synthetic inhibitor of MEK (MAPKK) has
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Received 27 June 2002; accepted 14 August 2002
*Correspondence: S-R Lin, Department of Clinical Pathology, Kaohsiung
Medical University, No 100, Shih-Chuan 1st Road, Kaohsiung, 80317,
Taiwan; E-mail: srlin@ms2.hinet.net
British Journal of Cancer (2002) 87, 1000–1005
ã 2002 Cancer Research UK All rights reserved 0007–0920/02 $25.00
www.bjcancer.comhigh speciﬁcity and has been used by other researchers. Some
studies have indicated that PD098059 failed to inhibit the stress,
the stimulated JNK/SAPK and the p38 pathways, demonstrating
its speciﬁcity for the ERK pathway (Alessi et al, 1995; Dudley et
al, 1995).
Interestingly, most patients with functional adrenocortical
tumours sought hospital treatment not owing to the pain caused
by the cancer but owing to the physiological imbalance caused
by excess secretion of cortisol. Therefore, the inﬂuence of hormone
secretion seems to be more signiﬁcant than that of cell growth
regulation in adrenocortical tumours. In the past, research regard-
ing cholesteroid regulation has often focused on the well known
regulation of elevated caused by adrenocorticotropic hormone
(ACTH) and Angiotensin II (Fredlund et al, 1975; Roskelley and
Auersperg, 1995; Toaff et al, 1979). Little is known concerning
the association hormone secretion of oncogenes with secretion
regulation. Based on our previous results, we assumed that the
active K-ras oncogene induced sterogenesis in adrenocortical cells
through Ras-to-MAPK pathway. To prove our assumption, we
used the mutant K-ras to activate the RAF/MEK (extracellular
signal-related kinase kinase)/MAPK/ERK pathway. In order to
understand whether mutant K-Ras activated C-Raf and MAP
kinase, we transfected the pK568MRSV, the inducible mutant K-
ras oncogene expression plasmid, into normal human adrenocorti-
cal cells (Wu et al, 2002). Then we analysed the level of RasGTP
during the extension time after IPTG treatment and the level of
phosphorylated c-Raf-1 and MAP kinase by Western blot. We used
a speciﬁc MAPK kinase (MEK) inhibitor, PD098050, to inhibit
signal transduction to observe whether mutant K-ras induced on
increase of mRNA levels of Cholesterol side-chain cleavage enzyme
(P450SCC), 17a-Hydroxylase/17, 20-lyase (P450c17) and 3b-Hydro-
xysteroid dehydrogenase (3bHSD) and the cortisol levels in
transfected cells. By doing this, we hope the mechanism of the
K-ras oncogene taking part in steroidogenesis will be further
understood.
MATERIALS AND METHODS
Mutant K-ras gene stably transfected human adrenocortical
cell culture
The cultured normal human adrenocortical cells synthesised and
secreted steroid hormones. The levels of cortisol and aldosterone
secretion indicated that the cultured cells were mainly fasciculata
reticularis cells with very few contaminating glomerulosa cells as
described previously (Wu et al, 2002). Cells (2610
5) in a 35-
mm plate were transfected with pOPRSV (control vector) and
pK568MRSV K-ras expression plasmids by CLONfectin method
(BD Biosciences Clontech, Palo Alto, CA, USA). Cells to be trans-
fected were removed from the cultures and the CLONfectin/DNA
media solution was gently applied. The plates were incubated at
378C for 1–4 h in a CO2 incubator. CLONfectin/DNA- media
solution was removed and then cells were washed with medium
or 16 phosphate buffer saline (PBS). Fresh complete growth
medium was added and the plates were incubating for another
48 h. Then the growth medium was changed to the medium
containing 400 mgm l
71 G418 (BD Biosciences Clontech) and
changed every 2 to 3 days to select the cell monoclone containing
expression plasmid.
Construction of GST-RBD of Raf-1 expression plasmid
Using the PCR we constructed the expression plasmid for minimal
Ras-binding domain of human Raf-1 (aa 51–131) from the human
liver Marathon-ready cDNA (BD Biosciences Clontech, CA, USA).
The oligonucleotides used to amplify a fragment of human c-raf-1
were 5'-CACAGATGGATCCAAGACAAGCAACAC-3' and 5'-GGG-
AAGAAT-TCACAGGAAATCTAC-3' (Herrmann et al, 1995)
cDNA. The resulting 412-base pair fragment was cleaved with
BamHI and EcoRI, puriﬁed, and cloned into the GST fusion vector
pGEX-4T-2 (Amersham, Pharmacia Biotech UK, Ltd) as described
previously (Lin et al, 2000). The resulting plasmid, pGEX-RBD,
was transformed into E. coli strain TG1. The correct orientation
of the RBD of Raf-1 cDNA was conﬁrmed by sequencing.
Expression and puriﬁcation of GST-RBD of Raf-1 fusion
protein
The expression of fusion protein was performed basically as
described by Guan and Dixon (1991). Twenty millilitres of an
overnight culture was inoculated into 1 l of 2XYT (10 g yeast
extract, 16 g tryptone and 5 g sodium chloride (NaCl) in 1 l)
containing 50 mgm l
71 ampicillin. The culture was incubated
vigorously at 378C until an absorption of one at 600 nm was
reached. IPTG was then added and cells were harvested by centri-
fugation and suspended in 10 ml PBST (2 mM EDTA, 0.1% b-
mercaptoethanol, 0.2 mM PMSF and 5 mM benzamidine) after
3 h incubation. Bacterial lysate was centrifuged at 48C to remove
the insoluble fraction. One millilitre of the bacterial supernatant
containing soluble proteins was mixed with 2 ml 50% (v v
71)
glutathione agarose beads and incubated 30 min at 48C with gentle
shaking. The agarose beads were washed four times with 10 ml
PBST. The fusion protein was eluted by competition with
glutathione using 262 min washes with 1 ml of 50 mM Tris
(pH 8.0) containing 10 mM glutathione. Free glutathione was
removed by dialysis against 50 mM Tris (pH 8.0), 150 mM NaCl,
0.1% b-mercaptoethanol. The puriﬁed GST-RBD of Raf-1 protein
was recovered.
Precipitation and immunoblot of active form RasGTP by
GST-RBD of Raf-1 fusion protein
The desired amount of crude GST-RBD of Raf-1 fusion protein
was incubated with glutathion-agarose beads at room temperature
for 30 min. The beads were isolated by centrifugation and washed
three times with RIPA buffer. Mutant K-ras gene stably transfected
human adrenocortical cells were grown in Ham’s F-12 medium
containing 10% foetal calf serum with 2.5 mM IPTG, and cells
from a 9 cm dish were lysed and scraped in 1 ml of RIPA buffer
containing 50 mM Tris pH 8.0, 150 mM NaCl, 0.5% doc, 1%
NP40, 0.1% SDS, 0.1 mM aprotinin, 1 mM leupeptin and 1 mM
PMSF at 48C. Lysates were centrifuged at 14000 r.p.m for 8 min
in an eppendorf centrifuge to remove nuclei. GST-RBD,
precoupled to glutathion-agarose-beads in RIPA buffer, was added
and the lysates were incubated at 48C for 30 min. Beads were
collected by centrifugation, washed three times with RIPA buffer
and resuspended in sample buffer (10% glycerol, 60 mM Tris,
pH 6.8. 2% SDS. 300 mM b-mercaptoethanol). The protein
samples were separated on vertical slab gels composed of 10%
polyacrylamide containing 0.1% sodium dodecyl sulphate (SDS)
prepared in 3 mM Tris-HCl, pH 8.8, as described previously (Lin
et al, 2000). Following electrophoresis, the protein was electro-
blotted to a nitrocellulose membrane (Schleicher & Schusll
GmbH, Dassel, Germany). The membrane ﬁxed with protein was
incubated with mouse monoclonal antibodies (mAbs) speciﬁc for
the K-ras p21 product (25 mg ml
71) (Santa Cruz Biotechnology,
Inc.), and the excess unbounded antibodies were then washed
off. The membrane binding with the mouse mAbs was incubated
with a solution of secondary goat anti-mouse IgG conjugated with
alkaline phosphatase (1:3000, Bio-Rad, Hercules, CA, USA) The
Ras protein was detected by enhanced chemiluminescence (ECL)
detection system (Amersham Pharmacia Biotech UK, Ltd). Blot
was then exposed to Kodak XAR ﬁlm (Eastman Kodak, Rochester,
NY, USA).
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The protein extracts, obtained from mutant K-ras gene stably
transfected human adrenocortical cell, were puriﬁed and electro-
phoresed through vertical slab gels as described above. Brieﬂy,
following electrophoresis, the proteins were transferred to a
nitro-cellulose membrane by an electrophoretic gel transfer device.
The membrane ﬁxed with proteins was incubated with mouse
monoclonal antibodies speciﬁc for the c-Raf-1, phosphorylated
raf-1 (p-raf-1), MAPK, phosphorylated MAPK (p-ERK, E-4) (Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA), respectively. The
membrane binding with the mouse mAbs was incubated with a
solution of secondary goat anti-mouse IgG conjugated with alka-
line phosphotase (1:3000, Bio-Rad, Hercules, CA, USA) The
target proteins were detected by enhanced chemiluminescence
(ECL) detection system (Amersham. Pharmacia Biotech UK Ltd).
Blot was then exposed to Kodak XAR ﬁlm (Eastman Kodak,
Rochester, NY, USA).
PD098059 MAPK Kinase inhibitor treatment
The pK568MRSV transfected adrenocortical cells were treated with
10 mM PD098059 for 45 min and then 2.5 mM IPTG was added.
The mixture was incubated for 36 h. The PD098059/IPTG-treated
cells were then ready for cortisol level detection and MAPK kinase
assay. The PD098059/IPTG-treated cell lysates and control cell
lysates were immunoprecipitated with anti-ERK monoclonal anti-
body (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA).
The immunocomplexes were then ready for MAP kinase assay.
MAP kinase assay
Proteins were obtained from K-ras expression plasmids transfected
cells and control cells. Supernatant (0.5 ml) containing 0.5 mg
protein was incubated with 10 ml of goat anti-ERK antibodies
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) for 2 h at
48C. The immunocomplexes were precipitated by centrifugation
and washed two times with buffers A, B (500 mM LiCl, 100 mM
Tris, 1 mM DTT, 0.1% Triton X-100; pH 7.6), and C (20 mM
MOPS, 2 mM EGTA, 10 mM MgC12, 1m M DTT, 0.1% Triton X-
100; pH 7.2), respectively ERK activities in the immunocomplexes
were measured (Alessi et al, 1995). Immunocomplexes were incu-
bated with 35 ml of buffer C supplemented with myelin basic
protein (MBP; 6 mg; Upstate Biotechnology), [g-
32P]ATP (5 mCi),
and MgCl2 (50 mM) for 20 min at 378C with vortexing every
5 min. To stop the reaction, 15 mlo f4 6 Laemmli buffer was
added, and the mixture was boiled for 5 min. Proteins in the
kinase reaction were resolved by SDS–PAGE (15% gel) and
subjected to autoradiography.
Northern blot
Total RNA was extracted with acid-guanidium phenol/chloroform
assay (AGPC) from transfected cells. Twenty micrograms of total
RNA was denatured with 6.5% formaldehyde and 50% formalde-
hyde for 15 min at 558C and separated by electrophoresis on
1.2% agarose gels containing 1.1% formaldehyde. Then RNA was
transferred to nylon membrane (Schleicher and Schuell GmbH,
Dassel, Germany) and ﬁxed. The blots were successively hybridised
with human P450SCC cDNA, human P450C17 cDNA, 3bHSD cDNA
and human b-actin cDNA. The hybridised ﬁlters were then washed
twice with washing buffer (Solution I: 36SSC, 0.5% SDS; Solution
II: 0.56SSC, 0.1% SDS) at 658C to wash off the unbounded probe.
The membrane was exposed to Kodak X-ﬁlm at –708C for auto-
radiography. b-actin signal was used to normalise data for the
above mRNA. All of the probes were conﬁrmed by direct sequen-
cing.
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Time 0          0        1         6       12       24       36       48
IPTG –          +         +          +        +         +         +         +
RasGTP
Ras
Figure 1 Time course of RasGTP formation after treatment with IPTG.
The normal human adrenocortical cells transfected with pK568MRSV plas-
mid were induced with 2.5 mM IPTG. Then the active RasGTP form was
precipitated by GST-RBD of Raf-1 fusion protein and immunoblotted as
described in Materials and Methods. The RasGTP levels were detected
at 0, 1, 6, 12, 24, 36 and 48 h after IPTG induction. Upper panels show
the amount of RasGTP; lower panels show total amount of Ras in 10%
of the extract. The amount of RasGTP was increased with the elongation
of IPTG induction. Plus (+) indicates when present; minus (7) indicates
when absent.
Time
IPTG
phosphoRaf-1
Total Raf-1
phosphoMAPK
MAPK
0         1        6        12       24      36      48
–         +        +         +         +        +        +
Figure 2 Time course of the phosphorylation of c-Raf1 and MAPK in
pK568MRSV transfected adrenocortical cells after treatment with IPTG.
Crude protein extract from transfected cells was electrophoresised and
transfered to PVDF as described in Materials and Methods. And then, it
was immunobloted with monoclonal antibodies speciﬁc to phosphorylated
c-Raf1 (p-Raf-1), phosphorylated MAPK and control c-Raf-1 and MAPK, re-
spectively. The amounts of phosphorylated c-Raf-1 (p-Raf-1) and phos-
phorylated MAPK; and control MAPK and c-Raf-1 were detected at 0, 1,
6, 12, 24, 36 and 48 h after IPTG induction. The amounts of phosphory-
lated c-Raf-1 and MAPK were increased with the elongation of IPTG treat-
ment. Plus (+) indicates when present; minus (7) indicates when absent.
Time
IPTG
PD098059
(10 µM)
MBP
0         1          6         12       24      36        36*
–          +         +          +          +         +          + 
–          –         –         –          –         –          +
Figure 3 The effect of PD098059 pretreatment and the time course of
MEK activity in pK568MRSV transfected adrenocortical cells after treatment
with IPTG. Kinase activity was measured using myelin basic protein (MBP)
as a substrate as described in Materials and Methods and signiﬁcantly in-
creased at 6, 12, 24 and 36 h after IPTG induction. *The 36* lane repre-
sented the pK568MRSV transfected cells treated with 10 mM PD098059
for 45 min before the addition of 2.5 mM IPTG and then incubation for
36 h in the presence of PD098059 and IPTG. With pretreatment of
PD098059, the MEK activity was obviously inhibited in pK568MRSV trans-
fected adrenocortical cells after treatment with IPTG. Plus (+) indicates
when present; minus (7) indicates when absent.
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The cell clones containing stable expression vector DNA were
cultured in a 6 mm culture plate. The supernatant was removed
for cortisol level detection. Standard solutions were diluted into
different concentrations (0, 1, 3, 10 and 60 mgd l
71), then 10 ml
of each standard solution and cell supernatant were each added
into a 96-well plate in which each well contained glass beads coated
with anti-cortisol IgG. An enzyme immunoassay assay and a
UBIMAGIWEL cortisol QUANTITATIVE kit (United Biotech
Inc., CA, USA) were used to detect and quantify the cortisol levels.
One hundred millitres of cortisol enzyme conjugate solution was
added into each well, mixed with the mixture, and then placed
at room temperature (22–278C) for 60 min. Next, the well was
washed with distilled water ﬁve times, followed by the addition
of solutions A and B, and mixed thoroughly and incubated at
room temperature for 30 min. A 50 ml stop solution (1 N
H2SO4) was then added to stop the reaction and the results were
qualiﬁed using an ELISA processor II (Boehring, Germany) at
450 nm. Finally, the cortisol levels were measured according to
the standard curve in mg per 10
6cells.
RESULTS
The normal human adrenocortical cells transfected with
pK568MRSV plasmid were induced with 2.5 mM IPTG., and the
active RasGTP form was precipitated by GST-RBD of Raf-1 fusion
protein and immunoblotted as described in Materials and Meth-
ods. The RasGTP levels were detected at 0, 1, 6, 12, 24, 36 and
48 h after IPTG induction (Figure 1). The results showed that
RasGTP levels in cells transfected with pK586MRSV increased with
induction time. The phosphorated c-Raf-1and phosphorated
MAPK levels increased signiﬁcantly at 1, 6, 12, 24 and 36 h after
IPTG induction. The results of this Western blot analysis also
revealed that phosphorylation of c-Raf-1 and MAPK was signiﬁ-
cantly enhanced when RasGTP level increased (Figure 2). Thus
the inducible mutant K-ras expression plasmid transfected adreno-
cortical cells expressed the mutant RasGTP in a time-dependent
manner after IPTG induction. Concurrently, the amount of phos-
phorylated c-Raf and phosphorylated MAPK increased.
Furthermore, the kinase activity of MEK (MAPK kinase) was
measured using myelin basic protein (MBP) as a substrate and
signiﬁcantly increased at 6, 12, 24 and 36 h after IPTG induction
(Figure 3). With pretreatment of 10 mM PD098059 for 45 min,
pK568MRSV transfected adrenocortical cells were then treated with
2.5 mM IPTG. The mixture solution was incubated for 36 h in the
presence of PD098059 and 2.5 mM IPTG. Then the MEK activity
was obviously inhibited (Figure 3, lane 36*
,). Moreover, steroido-
genesis study by Northern blot showed that the density of
mRNA of p450scc, p450c17 and 3bHSD at each period was
increased with time, but was also inhibited by PD098059 as shown
in Figure 4A. Thus, inhibition of MEK/MAPK pathway also inhib-
ited these enzymes
, synthesis. Consequently, the cortisol production
was increased signiﬁcantly at 1, 6, 12 and 24 h, and the increase of
cortisol production was also signiﬁcantly blocked by PD098059 at
36 h after IPTG induction (Figure 4). By using PD098059, the
MEK speciﬁc inhibitor, we could conﬁrm that mutant K-ras gene
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Figure 4 Effect of PD098059 on cortisol production or P450scc,
P450c17 and 3HSD mRNA in mutant K-ras gene transfected human adre-
nocortical cells. pK568MRSV or pOPRSVI transfected adrenocortical cells
were treated with IPTG for 1, 6, 12, 24 and 36 h. Then the total RNA
was extracted from the treated cells for Northern blot analysis. The histo-
gram revealed the densitometry data of Northern blot of p450scc,
p450c17 and 3HSD at every time point. The data indicates that their
mRNA levels increased with incubation time, however, the increase was
blocked by PD69859 as shown in lane 36*. Cortisol level in culture med-
ium was detected by EIA and was found to increase with the elongation of
IPTG induction. And the elevated level of cortisol was blocked shown in
(B) the 36* column. (B) *The 36* lane represented the pK568MRSV trans-
fected cells treated with 10 mM PD098059 for 45 min before the addition
of 2.5 mM IPTG and then incubation for 36 h in the presence of PD098059
and IPTG. Plus (+) indicates when present; minus (7) indicates when ab-
sent.
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through the Raf-MEK-MAPK pathway.
DISCUSSION
The present study showed that the adrenocortical cells transfected
with pK568MRSV, an inducible mutant K-ras expression plasmid,
expressed the mutant Ras protein in a time-dependent manner
after IPTG induction. At the same time, the amount of phosphory-
lated c-Raf and phosphorylated MAPK were also increased. To
clarify whether mutant K-ras gene regulated cortisol levels by
MEK/MAPK pathway, we used PD098059, a speciﬁc MEK inhibitor
(Alessi et al, 1995; Dudley et al, 1995), to block the signal transdu-
tion of the active RasGTP after IPTG induction. PD098059 is a
synthetic inhibitor of the Ras-MAPK pathway that speciﬁcally
blocks the activation of MEK. PD098059 has subsequently been
used as a tool to study MAPK signalling in various cell types
and in carcinogenesis (Reuter et al, 2000, blood). The inhibition
of MEK activation was demonstrated to prevent activation of
MAPKs (ERK-1/2) and subsequent phosphorylation of MAPK
substrates both in vitro and in intact cells (Alessi et al, 1995;
Dudley et al, 1995).
In this study, the addition of PD098059 led to the reduction of
the accumulation of P450scc, P450c17 and 3HSD mRNA after
IPTG-induction in transfected human adrenocortical cells by inhib-
ited Ras-MAPK pathway. PD098059 also reversed the increased
cortisol level in pK568MRSV transfected human adrenocortical
cells. In our previous study (Wu et al, 2002), we have proved that
lovastatin, a pharmacological inhibitor of p21
ras function (Roskel-
ley and Auersperg, 1995), also reversed the increased cortisol
level in mutant K-ras stably transfected human adrenocortical cells.
Taken together, these proved that the mutant K-ras gene enhanced
not only cell proliferation but also steroidogenesis in steroidogenic
phenotype cells by activating of Raf-MEK-MAPK signal transduc-
tion pathway.
Previous research on regulation of steroidogenesis mostly
focused on regulation of elevated hormone secretion caused by
ACTH and Angiotensin II (Toaff et al, 1979; Roskelley and Auer-
sperg, 1995). Little is known concerning the association of
oncogene with steroidogenesis regulation. Our study found that
the activation of genes encoding enzymes related to steroidogenesis
were regulated by activating cyclic Adenosine 3',5' monophosphate
(cAMP) regulatory protein to interact with speciﬁc sequences while
cAMP was used as secondary messenger. These cAMP regulatory
proteins included cAMP regulatory element-binding protein
(CREB), Steroidogenic factor (SF-1) and sp1 (Morohashi et al,
1992; Waterman et al, 1992; Omura and Morohashi, 1995). Cyto-
chrome P450scc(CYP11A1) removes the side chain of cholesterol
after cholesterol has been transferred into cells by steroidogenic
acute regulatory protein (StAP). It is, therefore, also an important
rate-limiting enzyme of steroidogenesis process in adrenocortical
cells (Miller, 1988). Cholesterol was then used as substrate to
produce different kinds of hormones via the action of 3bHSD,
P450c21 (CYP21B), P45017a (CYP17) and P450 11b(CYP11B1).
P450 regulatory enzymes were mainly regulated by cis-acting
elements on promoter region including cAMP-responsive
sequences (CRS), Ad4 and GC-rich sequences binding with corre-
sponding proteins (Morohashi et al, 1992; Begeot et al, 1993; Guo
et al, 1994; Tsukiyama et al, 1994; Omura and Morohashi, 1995).
Meanwhile, steroid 17a-hydroxylase and 3b-dehydrogenase can be
regulated by cyclic AMP and protein kinase C secondary messenger
system (Lund et al, 1997). Among all the positive gene regulations
in hormone production, CREB, a highly expressive transcription
factor in adrenal cortex, regulated steroid production by binding
with frequently present CREB binding site in the promoter region
of genes which encoding steroidogenic enzymes (Tsukiyama et al,
1994; Chung et al, 1997).
In many studies, the K-ras gene has been proven to take part
in cell growth regulation by activating MAP kinase to activate
transcription factor ELK-1 (Marais et al, 1993; Miranti et al,
1995). In 1996, Xing et al found that introduction of activated
ras oncogene into PC12 cells regulated gene expression by activat-
ing RAF and MAP kinase and then RSK2 of pp90RSK family to
phosphorylate CREB (Xing et al, 1996; Cesare et al, 1998; Beaupre
et al, 1999). The CREB was the earliest found to regulate gene
expression when the level of cAMP increases (Bonni et al,
1995). It also participates in the regulation of the cell response
after the binding of growth factors with receptors (Bohm et al,
1995). Furthermore, CREB is a transcription factor for genes
corresponding to steroidogenesis related enzymes (Watanabe et
al, 1994; Kagawa et al, 1999). In this study, our laboratory proved
that the mutant Ras protein enhanced not only the cell prolifera-
tion but also the steroidogenesis in steroidogenic phenotype cells
by activation of Raf-MEK-MAPK signal transduction pathway.
Therefore, in the future, we will use the cDNA microarray and
other tools to examine the difference between the control cell
and the K-ras transfected cell to understand the cross talks
between the Ras-to-MAPK pathway and the regulation of the
steroidogenesis process.
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